Gut Impact Factor

The first signal is status. Gut is operating at the top of the GI ladder, not as a second-choice clinical venue.

The second signal is normalized strength. The JCI of 5.51 is extremely high, which tells you the journal is not just benefiting from a citation-heavy field. It is performing well above category average after normalization.

The third signal is durability and cleanliness. The five-year JIF of 25.3 is almost identical to the current JIF, and the JIF without self-cites is 25.0. That means the headline number is both persistent and clean.

The Scopus impact score of 14.49, SJR of 8.874, and h-index of 364 reinforce that this is one of the clearest owner journals for high-consequence GI and hepatology work.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is down from 15.00 in 2023 to 14.49 in 2024, but still substantially above the mid-2010s range. The stronger point is that Gut remains one of the top GI journals even after the field's peak citation years cooled.

This is the profile of a stable flagship, not a temporary boom.

The common mistake is to see a very high impact factor and assume the journal is mostly screening for prestige or novelty in the abstract.

That is not how Gut usually reads manuscripts. Editors are generally asking:

• does the paper have clear GI or liver consequence
• is the translational value visible early
• does the significance box make a specific patient-facing case
• is the story mechanistic or clinically useful enough to justify a top-tier broad GI desk

BMJ's Gut author materials are unusually explicit that the journal is oriented toward work likely to affect clinical practice, and that matters when authors interpret the number. A very strong observational signal can still fail here if the manuscript never closes the loop from finding to mechanism, management, or patient consequence.

That means the metric confirms Gut is elite. It does not substitute for translational legibility.

In our pre-submission review work on manuscripts targeting Gut, the repeat problem is a respectable study with insufficient clinical or mechanistic consequence on page one.

Gut tends to punish manuscripts that need the discussion section to explain why patients or clinicians should care.

In our pre-submission review work on manuscripts targeting Gut, four failure patterns recur.

The paper is descriptive. This is common in cohort, biomarker, or microbiome work that never gets to mechanism or action.

The significance box stays generic. Editors use that section as a real triage device, not a formality.

The translational payoff is implied rather than shown. The manuscript may be interesting, but it is still one step short of clinical consequence.

The study is good, but the cleaner owner is elsewhere. Many liver-heavy or practice-heavy papers belong more naturally in Hepatology or CGH.

If that sounds familiar, a Gut submission readiness check is usually more useful than another round of language polishing.

The impact factor does not tell you whether the significance box is strong enough, whether the translational logic is visible enough, or whether the paper is better owned by a different GI or liver journal.

That is where the metric can be misleading. It tells you Gut is elite. It does not tell you that your manuscript is a Gut manuscript.